News

Neonatal fragment crystallizable receptor (FcRn) inhibitors could significantly decrease complications associated with FNAIT, recent studies show.

Results from the phase 1 clinical trial of RLYB212, an experimental therapy intended for FNAIT prevention, were recently published.

A new study to compare treatment with nipocalimab versus IVIG in pregnant people at risk of FNAIT will be enrolling patients soon.

A new registry of human platelet antigen (HPA)–typed blood donors may help treat fetal and neonatal alloimmune thrombocytopenia (FNAIT) in Greece.

A case report described a wrongful diagnosis of FNAIT that could have been prevented if HPA genotyping had been performed sooner.

According to a recent poster presentation, women with FNAIT reported negative effects on their emotional and physical health.

In a recent study, mothers affected by FNAIT reported their diagnosis had a significant negative effect on their well-being.

Johnson & Johnson has announced the FDA’s fast track approval of nipocalimab for treating FNAIT in alloimmunized pregnant persons.

BillionToOne will allow its UNITY fetal antigen test to be used to test patients in the phase 3 trial evaluating the safety and efficacy of nipocalimab.